Table 2.

Compilation of experiments treating established B16-OVA tumors with A1-R SIINF and/or antibodies

B16 OVA tumor at treatmentTumor rejection in experiment #
TreatmentTumor size, mm3Duration of growth, d123456Total
αCTLA-4 + αPD-L1115 ± 1128 ± 100/20/30/5
A1-R SIINF + αCD8125 ± 1617 ± 10/10/60/7
A1-R SIINF + αCTLA-4119 ± 1025 ± 50/30/10/4
A1-R SIINF + αPD-L1122 ± 920 ± 12/32/24/5a
A1-R SIINF + αCTLA-4 + αPD-L1121 ± 919 ± 81/10/12/21/14/5a
  • aP < 0.05 compared with the αCTLA-4 + αPD-L1 group.